FDA's Drug Advertising Oversight Gets A Promotion From A Division To An Office
This article was originally published in The Pink Sheet Daily
Executive Summary
The Division of Drug, Advertising, Marketing and Communications will consist of an office with two divisions, one to review materials for healthcare professionals and other to review direct-to-consumer promotions.
You may also be interested in...
FDA’s Promotional Assessments Reorganized Around Specialty, Not Target Audience
The two divisions within the Office of Prescription Drug Promotion are renamed the divisions of advertising and promotion review I and II; they will each have four teams operating within them in a structure akin to the Office of New Drugs.
FDA’s Rx Enforcement Letter Output Drops In 2011; OPDP Sees Improvement In Promotions
The 30 letters issued are the lowest since 2008, but FDA says the number is only part of its enforcement strategy.
DTC Pre-Review Guidance In The Works For Rx TV Ads, FDA’s Abrams Says
Certain drug classes will be required to submit certain types of ads, according to Tom Abrams, director of CDER’s recently elevated Office of Prescription Drug Promotion, but specifics will await the guidance itself.